Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis : to Webcast Fireside Chats as Part of Virtual Investor Conferences in November

11/02/2020 | 04:10pm EST

– Presentations to be webcast on www.exelixis.com

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in November:

  • Credit Suisse 29th Annual Virtual Healthcare Conference: Exelixis is scheduled to present at 4:15 p.m. EST/ 1:15 p.m. PST on Tuesday, November 10, 2020.
  • Stifel 2020 Virtual Healthcare Conference: Exelixis is scheduled to present at 2:00 p.m. EST/ 11:00 a.m. PST on Wednesday, November 18, 2020.

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune’s 100 Fastest-Growing Companies for the first time, ranking 17th overall and the third-highest biopharmaceutical company. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.


© Business Wire 2020
All news about EXELIXIS, INC.
01/11EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/11EXELIXIS : Reports Preliminary Q4 Revenue of $270 Million, Issues 2021 Guidance
MT
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2020 Financial Res..
BU
01/04EXELIXIS : to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conferen..
BU
2020EXELIXIS : Announces Cabozantinib Significantly Improved Progression-Free Surviv..
AQ
2020EXELIXIS : Phase 3 Study of Cabometyx in Thyroid Cancer Meets Co-Primary Endpoin..
MT
2020EXELIXIS : Announces Cabozantinib Significantly Improved Progression-Free Surviv..
BU
2020EXELIXIS : XWPharma Names Michael M. Morrissey, PhD to Board of Directors
AQ
2020Dr. Reddy's Unit Signs In-Licensing Deal with US Drug Discovery Company Exeli..
MT
2020INSIDER TRENDS : Regulus Therapeutics Insider Gets Stock Award, Extends Buy Tren..
MT
More news
Financials (USD)
Sales 2020 988 M - -
Net income 2020 99,7 M - -
Net cash 2020 1 494 M - -
P/E ratio 2020 81,3x
Yield 2020 -
Capitalization 7 361 M 7 361 M -
EV / Sales 2020 5,94x
EV / Sales 2021 4,64x
Nbr of Employees 617
Free-Float 98,0%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 30,83 $
Last Close Price 23,73 $
Spread / Highest target 56,0%
Spread / Average Target 30,0%
Spread / Lowest Target 5,37%
EPS Revisions
Managers and Directors
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.18.21%7 361
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458